Sonic Healthcare – Buy

Sonic Healthcare 1H21 Revenue $4.4bn, up 33% on the same time last year. EBITDA increased to $1.02bn and further growth of 5 – 10% into FY22 underpins our buy recommendation.

The balance sheet remains under-geared and we expect to see the company actively seeking M&A or JV opportunities.

You’re not a member!  Trial today

SHL trades on a forward yield of 3.8%

Ready to elevate your investing?

Join Investor Signals today and start your journey to better, more disciplined returns.